Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310


Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis.

Woo S, Han S, Kim TH, Suh CH, Westphalen AC, Hricak H, Zelefsky MJ, Vargas HA.

AJR Am J Roentgenol. 2019 Dec 4:1-8. doi: 10.2214/AJR.19.21836. [Epub ahead of print]


Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.

Zelefsky MJ, Pinitpatcharalert A, Kollmeier M, Goldman DA, McBride S, Gorovets D, Zhang Z, Varghese M, Happersett L, Tyagi N, Hunt M.

Eur Urol Oncol. 2019 Oct 23. pii: S2588-9311(19)30147-6. doi: 10.1016/j.euo.2019.09.006. [Epub ahead of print]


Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data.

Weg ES, Pei X, Kollmeier MA, McBride SM, Zelefsky MJ.

Adv Radiat Oncol. 2019 Apr 4;4(3):492-499. doi: 10.1016/j.adro.2019.03.012. eCollection 2019 Jul-Sep.


Comparison of Motion-Insensitive T2-Weighted MRI Pulse Sequences for Visualization of the Prostatic Urethra During MR Simulation.

Zakian KL, Wibmer A, Vargas HA, Alberts E, Kadbi M, Mychalczak B, Kollmeier M, Gorovets D, McBride S, Hunt M, Zelefsky MJ, Tyagi N.

Pract Radiat Oncol. 2019 Nov;9(6):e534-e540. doi: 10.1016/j.prro.2019.06.009. Epub 2019 Jun 25.


Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Woo S, Suh CH, Eastham JA, Zelefsky MJ, Morris MJ, Abida W, Scher HI, Sidlow R, Becker AS, Wibmer AG, Hricak H, Vargas HA.

Eur Urol Oncol. 2019 Nov;2(6):605-616. doi: 10.1016/j.euo.2019.05.004. Epub 2019 Jun 14. Review.


Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy.

Patel MA, Kollmeier M, McBride S, Gorovets D, Varghese M, Chan L, Knezevic A, Zhang Z, Zelefsky MJ.

Radiother Oncol. 2019 Nov;140:34-40. doi: 10.1016/j.radonc.2019.04.003. Epub 2019 Jun 6.


Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer.

Pinitpatcharalert A, Happersett L, Kollmeier M, McBride S, Gorovets D, Tyagi N, Varghese M, Zelefsky MJ.

Adv Radiat Oncol. 2019 Jan 31;4(2):337-344. doi: 10.1016/j.adro.2018.12.001. eCollection 2019 Apr-Jun.


Brachytherapy: Expanding the horizons.

Shah C, Zelefsky MJ.

Brachytherapy. 2019 May - Jun;18(3):241. doi: 10.1016/j.brachy.2019.01.003. Epub 2019 Mar 16. No abstract available.


Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.

Zelefsky MJ, Goldman DA, Reuter V, Kollmeier M, McBride S, Zhang Z, Varghese M, Pei X, Fuks Z.

J Urol. 2019 Jun;201(6):1127-1133. doi: 10.1097/JU.0000000000000110.


Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.

Zelefsky MJ, Kollmeier M, McBride S, Varghese M, Mychalczak B, Gewanter R, Garg MK, Happersett L, Goldman DA, Pei I, Lin M, Zhang Z, Cox BW.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):42-49. doi: 10.1016/j.ijrobp.2018.12.045. Epub 2019 Jan 4.


Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury.

Bodo S, Campagne C, Thin TH, Higginson DS, Vargas HA, Hua G, Fuller JD, Ackerstaff E, Russell J, Zhang Z, Klingler S, Cho H, Kaag MG, Mazaheri Y, Rimner A, Manova-Todorova K, Epel B, Zatcky J, Cleary CR, Rao SS, Yamada Y, Zelefsky MJ, Halpern HJ, Koutcher JA, Cordon-Cardo C, Greco C, Haimovitz-Friedman A, Sala E, Powell SN, Kolesnick R, Fuks Z.

J Clin Invest. 2019 Feb 1;129(2):786-801. doi: 10.1172/JCI97631. Epub 2019 Jan 14.


The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines.

Chang AJ, McBride S, Keyes M, Chung HT, Davis BJ, Cox BW, Crook J, Demanes DJ, Hsu IC, Kamrava M, Krauss DJ, Morton G, Orio Iii PF, Roach Iii M, Venkat PS, Vigneault E, Zelefsky MJ.

J Clin Oncol. 2018 Sep 13:JCO1800626. doi: 10.1200/JCO.18.00626. [Epub ahead of print] No abstract available.


Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control.

Munck Af Rosenschold P, Zelefsky MJ, Apte AP, Jackson A, Oh JH, Shulman E, Desai N, Hunt M, Ghadjar P, Yorke E, Deasy JO.

Radiat Oncol. 2018 Apr 12;13(1):64. doi: 10.1186/s13014-018-0978-1.


Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy.

Thor M, Jackson A, Zelefsky MJ, Steineck G, Karlsdòttir A, Høyer M, Liu M, Nasser NJ, Petersen SE, Moiseenko V, Deasy JO.

Radiother Oncol. 2018 Apr;127(1):88-95. doi: 10.1016/j.radonc.2018.02.020. Epub 2018 Mar 9.


Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.

Romesser PB, Pei X, Shi W, Zhang Z, Kollmeier M, McBride SM, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):59-67. doi: 10.1016/j.ijrobp.2017.09.003. Epub 2017 Oct 13.


Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.

Taggar AS, Charas T, Cohen GN, Boonyawan K, Kollmeier M, McBride S, Mathur N, Damato AL, Zelefsky MJ.

Brachytherapy. 2018 Mar - Apr;17(2):251-258. doi: 10.1016/j.brachy.2017.11.006. Epub 2017 Dec 11.


Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.

Kollmeier MA, McBride S, Taggar A, Anderson E, Lin M, Pei X, Weiji S, Voros L, Cohen G, Yamada Y, Zelefsky MJ.

Brachytherapy. 2017 Nov - Dec;16(6):1091-1098. doi: 10.1016/j.brachy.2017.07.013. Epub 2017 Aug 21.


Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials.

Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, Kim DWN, Hornberger B, Dubas J, Laine AM, Zelefsky MJ, Timmerman RD, Folkert MR.

Med Dosim. 2017 Winter;42(4):341-347. doi: 10.1016/j.meddos.2017.07.002. Epub 2017 Jul 31.


Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.

Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z.

BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3.


Real-time intraoperative evaluation of implant quality and dose correction during prostate brachytherapy consistently improves target coverage using a novel image fusion and optimization program.

Zelefsky MJ, Cohen GN, Taggar AS, Kollmeier M, McBride S, Mageras G, Zaider M.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):319-324. doi: 10.1016/j.prro.2017.01.009. Epub 2017 Jan 20.


American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.

Keyes M, Merrick G, Frank SJ, Grimm P, Zelefsky MJ.

Brachytherapy. 2017 Mar - Apr;16(2):245-265. doi: 10.1016/j.brachy.2016.11.017. Epub 2017 Jan 16. Review.


Second malignancy risk in prostate cancer and radiotherapy.

Charas T, Taggar A, Zelefsky MJ.

Future Oncol. 2017 Feb;13(5):385-389. doi: 10.2217/fon-2016-0503. Epub 2017 Jan 17. No abstract available.


The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery.

Yamada Y, Katsoulakis E, Laufer I, Lovelock M, Barzilai O, McLaughlin LA, Zhang Z, Schmitt AM, Higginson DS, Lis E, Zelefsky MJ, Mechalakos J, Bilsky MH.

Neurosurg Focus. 2017 Jan;42(1):E6. doi: 10.3171/2016.9.FOCUS16369.


Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy.

Lis E, Saha A, Peck KK, Zatcky J, Zelefsky MJ, Yamada Y, Holodny AI, Bilsky MH, Karimi S.

Neurosurg Focus. 2017 Jan;42(1):E9. doi: 10.3171/2016.9.FOCUS16378.


A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

O'Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC, Laudone VP, Bochner BH, Sheinfeld J, Dayan ES, Bellomo LP, Sjoberg DD, Heller G, Zelefsky MJ, Eastham JA, Scardino PT, Scher HI.

Urology. 2017 Apr;102:164-172. doi: 10.1016/j.urology.2016.10.044. Epub 2016 Nov 22.


Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?

Zelefsky MJ, Kollmeier MA, Gorshein E, Pei X, Torres M, McBride S, Happersett L, Cohen GN, Yamada Y.

Radiother Oncol. 2016 Oct;121(1):109-112. doi: 10.1016/j.radonc.2016.08.010. Epub 2016 Oct 15.


American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.

Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, Zelefsky MJ.

Brachytherapy. 2017 Jan - Feb;16(1):1-12. doi: 10.1016/j.brachy.2016.09.006. Epub 2016 Oct 19. Review.


High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck.

Teckie S, Lok BH, Rao S, Gutiontov SI, Yamada Y, Berry SL, Zelefsky MJ, Lee NY.

Oral Oncol. 2016 Sep;60:74-80. doi: 10.1016/j.oraloncology.2016.06.016. Epub 2016 Jul 12.


Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, Zelefsky MJ.

Eur Urol. 2017 Jan;71(1):37-43. doi: 10.1016/j.eururo.2016.07.043. Epub 2016 Aug 11.


Genomic characterization of response to chemoradiation in urothelial bladder cancer.

Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G.

Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.


Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?

Vargas HA, Martin-Malburet AG, Takeda T, Corradi RB, Eastham J, Wibmer A, Sala E, Zelefsky MJ, Weber WA, Hricak H.

Urol Oncol. 2016 Nov;34(11):482.e5-482.e10. doi: 10.1016/j.urolonc.2016.05.026. Epub 2016 Jun 23.


Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.

Nasser NJ, Cohen GN, Dauer LT, Zelefsky MJ.

Brachytherapy. 2016 Jul-Aug;15(4):420-425. doi: 10.1016/j.brachy.2016.03.012. Epub 2016 May 12.


Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.

Spratt DE, Osborne JR, Zumsteg ZS, Rebeiz K, Leeman J, Rivera A, Morris MJ, Zelefsky MJ.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):271-6. doi: 10.1038/pcan.2016.14. Epub 2016 Apr 26.


Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapy.

King MT, Nasser NJ, Mathur N, Cohen GN, Kollmeier MA, Yuen J, Vargas HA, Pei X, Yamada Y, Zakian KL, Zaider M, Zelefsky MJ.

Brachytherapy. 2016 May-Jun;15(3):266-273. doi: 10.1016/j.brachy.2016.02.003. Epub 2016 Apr 20.


Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.

Thaker NG, Pugh TJ, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orio PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ.

Brachytherapy. 2016 May-Jun;15(3):274-282. doi: 10.1016/j.brachy.2016.01.003. Epub 2016 Feb 23.


High- and low-dose-rate intraoperative radiotherapy for thoracic malignancies resected with close or positive margins.

Fleming C, Rimner A, Cohen GN, Woo KM, Zhang Z, Rosenzweig KE, Alektiar KM, Zelefsky MJ, Bains MS, Wu AJ.

Brachytherapy. 2016 Mar-Apr;15(2):208-15. doi: 10.1016/j.brachy.2015.11.007. Epub 2016 Jan 26.


Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer.

Zelefsky MJ, Poon BY, Eastham J, Vickers A, Pei X, Scardino PT.

Radiother Oncol. 2016 Jan;118(1):85-91. doi: 10.1016/j.radonc.2015.11.035. Epub 2016 Jan 9.


Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer.

Kohutek ZA, Weg ES, Pei X, Shi W, Zhang Z, Kollmeier MA, Zelefsky MJ.

Urology. 2016 Jan;87:146-52. doi: 10.1016/j.urology.2015.08.029. Epub 2015 Oct 22.


A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA.

Eur Urol. 2016 Mar;69(3):428-35. doi: 10.1016/j.eururo.2015.06.046. Epub 2015 Jul 10.


Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.

Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, McBride S, Yamada Y, Zelefsky MJ.

J Urol. 2015 Dec;194(6):1624-30. doi: 10.1016/j.juro.2015.06.100. Epub 2015 Jul 10.


Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma.

Zumsteg ZS, Riaz N, Jaffery S, Hu M, Gelblum D, Zhou Y, Mychalczak B, Zelefsky MJ, Wolden S, Rao S, Lee NY.

Oral Oncol. 2015 Jul;51(7):716-23. doi: 10.1016/j.oraloncology.2015.02.003. Epub 2015 May 7.


Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.

Hötker AM, Mazaheri Y, Zheng J, Moskowitz CS, Berkowitz J, Lantos JE, Pei X, Zelefsky MJ, Hricak H, Akin O.

Eur Radiol. 2015 Sep;25(9):2665-72. doi: 10.1007/s00330-015-3688-1. Epub 2015 Mar 29.


Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy.

Lovelock DM, Messineo AP, Cox BW, Kollmeier MA, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):588-94. doi: 10.1016/j.ijrobp.2014.10.049. Epub 2015 Jan 30.


Long-Term Survival After High-Dose-Rate Brachytherapy for Locally Advanced or Recurrent Colorectal Adenocarcinoma.

Terezakis S, Morikawa L, Wu A, Zhang Z, Shi W, Weiser MR, Paty PB, Guillem J, Temple L, Nash GM, Zelefsky MJ, Goodman KA.

Ann Surg Oncol. 2015 Jul;22(7):2168-78. doi: 10.1245/s10434-014-4271-8. Epub 2015 Jan 29.


Volume and landmark analysis: comparison of MRI measurements obtained with an endorectal coil and with a phased-array coil.

Mazaheri Y, Afaq AA, Jung SI, Goldman DA, Wang L, Aslan H, Zelefsky MJ, Akin O, Hricak H.

Clin Radiol. 2015 Apr;70(4):379-86. doi: 10.1016/j.crad.2014.12.002. Epub 2014 Dec 29.


Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer.

Cuaron J, Pei X, Cohen GN, Cox BW, Yamada Y, Zelefsky MJ, Kollmeier MA.

Brachytherapy. 2015 Mar-Apr;14(2):179-84. doi: 10.1016/j.brachy.2014.05.019. Epub 2014 Dec 12.


External beam radiation therapy for small cell carcinoma of the urinary bladder.

Mattes MD, Kan CC, Dalbagni G, Zelefsky MJ, Kollmeier MA.

Pract Radiat Oncol. 2015 Jan-Feb;5(1):e17-22. doi: 10.1016/j.prro.2014.03.013. Epub 2014 May 28.


Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity.

Steinberger E, Kollmeier M, McBride S, Novak C, Pei X, Zelefsky MJ.

BJU Int. 2015 Oct;116(4):596-603. doi: 10.1111/bju.12969. Epub 2015 Jan 27.


Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.

Spratt DE, Zumsteg ZS, Pei X, Romesser PB, Yamada J, Kollmeier MA, Woo K, Zhang Z, Zelefsky MJ.

Prostate. 2015 Feb;75(2):175-82. doi: 10.1002/pros.22902. Epub 2014 Oct 18.

Supplemental Content

Loading ...
Support Center